Adults and children over 1 year:
It can be applied in open treatment, as a thin layer on the affected skin area, two to three times a day, gently rubbing until completely absorbed.
It can also be applied in occlusive treatment, as a thin layer on the affected skin area, once a day, covering it with a non-porous plastic dressing.
Your doctor will indicate the duration of your treatment; usually one week.
Depending on the severity of the condition, treatment may be prolonged from 1 to 4 weeks. If there is no improvement within this time period, your doctor must reevaluate the treatment.
Treatment should not exceed 2 months.
Use in children
It is not recommended for use in children under 1 year.
It is not recommended to use occlusive dressings (such as in the diaper area).
In children, treatment should be limited to short periods of time and the minimum effective amount of medication should be used. If used on the face, treatment should not exceed 5 days, and in general, not more than one week in other body areas.
If you use more Synalar gamma than you should
The use of excessive amounts of cream can cause adrenal suppression (which results in an alteration of normal hormone production). In this case, treatment should be interrupted and your doctor should monitor your adrenal hormonal axis function.
An accidental ingestion may cause tachycardia (acceleration of heart rate) and occasional elevations in blood pressure, which resolve without the need for medical treatment.
If you have used this medication more than you should, consult your doctor, pharmacist, or call the Toxicology Information Service, phone 91-562 04 20, indicating the medication and the amount used.
If you forgot to use Synalar gamma
Do not apply a double dose to compensate for the missed doses.
If you forget to apply the cream at the scheduled time, apply it as soon as you remember and then continue as before.
If you have any other questions about the use of this medication, ask your doctor or pharmacist.
Like all medications, this medication may produce adverse effects, although not all people will experience them.
Rare Adverse Effects (may affect up to 1 in 1,000 people):
- Skin atrophy with epidermal thinning (often irreversible)
- Telangiectasia (dilation of small blood vessels on the skin surface)
- Purpura (presence of red patches and spots on the skin)
- Striae on the skin
- Acneiform eruptions (acne-like eruptions)
- Perioral dermatitis (small red papules around the mouth)
- Skin depigmentation (loss of skin coloration)
- Dermatitis and eczema, including contact dermatitis
- Burning sensation
- Rebound effect.
Very Rare Adverse Effects (may affect up to 1 in 10,000 people):
- Adrenal suppression, which causes an alteration in normal hormone production.
Unknown Frequency (cannot be estimated from available data):
- Hypersensitivity (allergic reactions)
- Pruritus (itching)
- Dry skin
-Miliaria (alteration caused by obstruction of sweat glands, resulting in the appearance of white or red grains on various parts of the body) or prickly heat
- Skin maceration
- Hirsutism (excessive hair growth)
- Folliculitis (inflammation of one or more hair follicles)
- Secondary infection.
Reporting Adverse Effects
If you experience any type of adverse effect, consult your doctor, pharmacist, or nurse, even if
it is a possible adverse effect not listed in this prospectus. You can also report them directly through the Spanish System for Pharmacovigilance of Medicinal Products for Human Use:
www.notificaRAM.es.MReporting adverse effects can help provide more information on the safety of this medication.
Keep this medication out of the sight and reach of children.
Do not use this medication after the expiration date that appears on the packaging after CAD. The expiration date is the last day of the month indicated.
Medications should not be thrown down the drains or in the trash. Dispose of the packaging and themedications that you no longer need at the SIGRE collection pointof the pharmacy. If in doubt, ask yourpharmacist how to dispose of the packaging and the medications that you no longer need. By doing so, you will help protect the environment.
Composition of Synalar gamma
-The active ingredient is acetonide of fluocinolone. Each gram of cream contains 0.1 mg of acetonide of fluocinolone.
- The other components are: cetyl alcohol, stearyl alcohol, sorbitan stearate,
polysorbate 60 (E-435), liquid paraffin, methyl parahydroxybenzoate (E-218), propyl parahydroxybenzoate (E-216), propylene glycol (E-1520), anhydrous citric acid (E-330) and purified water.
Appearance of Synalar gamma and content of the packaging
Homogeneous cream of white color packaged in aluminum tubes and HDPE screw cap. It is presented in tubes of 30 and 60 grams of cream.
Only some sizes of packaging may be commercially marketed.
Holder of the marketing authorization
Tora Laboratories, S.L.U.
Avenida de Oporto, 60
28019 Madrid, Spain
Responsible for manufacturing
Temmler Italia S.R.L.
Via delle Industrie, 2 - 280061 Carugate – Milan - Italy
Date of the last review of this leaflet: October/2020
The detailed and updated information of this medicine is available on the website of the Spanish Agency of Medicines and Medical Devices (AEMPS)
Есть вопросы по этому лекарству или вашим симптомам? Свяжитесь с лицензированным врачом для получения помощи и персонализированного ухода.